These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 29966732)

  • 1. Patients and investigators prefer measures of absolute risk in subgroups for pragmatic randomized trials.
    Murray EJ; Caniglia EC; Swanson SA; Hernández-Díaz S; Hernán MA
    J Clin Epidemiol; 2018 Nov; 103():10-21. PubMed ID: 29966732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stakeholder views regarding ethical issues in the design and conduct of pragmatic trials: study protocol.
    Nicholls SG; Carroll K; Brehaut J; Weijer C; Hey SP; Goldstein CE; Zwarenstein M; Graham ID; McKenzie JE; McIntyre L; Jairath V; Campbell MK; Grimshaw JM; Fergusson DA; Taljaard M
    BMC Med Ethics; 2018 Nov; 19(1):90. PubMed ID: 30458809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stakeholders' views on the ethical challenges of pragmatic trials investigating pharmaceutical drugs.
    Kalkman S; van Thiel GJ; Grobbee DE; Meinecke AK; Zuidgeest MG; van Delden JJ;
    Trials; 2016 Aug; 17(1):419. PubMed ID: 27550379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Framing the conversation: use of PRECIS-2 ratings to advance understanding of pragmatic trial design domains.
    Lipman PD; Loudon K; Dluzak L; Moloney R; Messner D; Stoney CM
    Trials; 2017 Nov; 18(1):532. PubMed ID: 29126437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unresolved issues with noninferiority pragmatic trials: Results of a literature survey.
    Ciarleglio MM; Li J; Peduzzi P
    Clin Trials; 2024 Apr; 21(2):242-256. PubMed ID: 37927102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Per-Protocol Analyses of Pragmatic Trials.
    Hernán MA; Robins JM
    N Engl J Med; 2017 Oct; 377(14):1391-1398. PubMed ID: 28976864
    [No Abstract]   [Full Text] [Related]  

  • 7. Real-world evidence: How pragmatic are randomized controlled trials labeled as pragmatic?
    Dal-Ré R; Janiaud P; Ioannidis JPA
    BMC Med; 2018 Apr; 16(1):49. PubMed ID: 29615035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Series: Pragmatic trials and real world evidence: Paper 7. Safety, quality and monitoring.
    Irving E; van den Bor R; Welsing P; Walsh V; Alfonso-Cristancho R; Harvey C; Garman N; Grobbee DE;
    J Clin Epidemiol; 2017 Nov; 91():6-12. PubMed ID: 28502812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The importance of decision intent within descriptions of pragmatic trials.
    Nicholls SG; Zwarenstein M; Hey SP; Giraudeau B; Campbell MK; Taljaard M
    J Clin Epidemiol; 2020 Sep; 125():30-37. PubMed ID: 32422248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pragmatic randomized trials in drug development pose new ethical questions: a systematic review.
    Kalkman S; van Thiel GJ; Grobbee DE; van Delden JJ
    Drug Discov Today; 2015 Jul; 20(7):856-62. PubMed ID: 25794600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Good intentions and ICH-GCP: Trial conduct training needs to go beyond the ICH-GCP document and include the intention-to-treat principle.
    Browne LH; Graham PH
    Clin Trials; 2014 Dec; 11(6):629-34. PubMed ID: 25023199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the design and reporting of pragmatic trials in osteoarthritis research.
    Ali SA; Kloseck M; Lee K; Walsh KE; MacDermid JC; Fitzsimmons D
    Rheumatology (Oxford); 2018 Jan; 57(1):59-63. PubMed ID: 28371879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence adjustment in the Coronary Drug Project: A call for better per-protocol effect estimates in randomized trials.
    Murray EJ; Hernán MA
    Clin Trials; 2016 Aug; 13(4):372-8. PubMed ID: 26951361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Series: Pragmatic trials and real world evidence: Paper 3. Patient selection challenges and consequences.
    Oude Rengerink K; Kalkman S; Collier S; Ciaglia A; Worsley SD; Lightbourne A; Eckert L; Groenwold RHH; Grobbee DE; Irving EA;
    J Clin Epidemiol; 2017 Sep; 89():173-180. PubMed ID: 28502808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individual point-of-care trials: a new approach to incorporate patient's preferences into personalized pragmatic clinical trials.
    Sacristán JA; Knottnerus JA
    J Clin Epidemiol; 2021 Feb; 130():152-155. PubMed ID: 33002636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Series: Pragmatic trials and real world evidence: Paper 5. Usual care and real life comparators.
    Zuidgeest MGP; Welsing PMJ; van Thiel GJMW; Ciaglia A; Alfonso-Cristancho R; Eckert L; Eijkemans MJC; Egger M;
    J Clin Epidemiol; 2017 Oct; 90():92-98. PubMed ID: 28694123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methodological Challenges and Statistical Approaches in the COMprehensive Post-Acute Stroke Services Study.
    Psioda MA; Jones SB; Xenakis JG; D'Agostino RB
    Med Care; 2021 Aug; 59(Suppl 4):S355-S363. PubMed ID: 34228017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cohort multiple randomized controlled trial design: a valid and efficient alternative to pragmatic trials?
    van der Velden JM; Verkooijen HM; Young-Afat DA; Burbach JP; van Vulpen M; Relton C; van Gils CH; May AM; Groenwold RH
    Int J Epidemiol; 2017 Feb; 46(1):96-102. PubMed ID: 27118559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Series: Pragmatic trials and real world evidence: Paper 6. Outcome measures in the real world.
    Welsing PM; Oude Rengerink K; Collier S; Eckert L; van Smeden M; Ciaglia A; Nachbaur G; Trelle S; Taylor AJ; Egger M; Goetz I;
    J Clin Epidemiol; 2017 Oct; 90():99-107. PubMed ID: 28502810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond the intention-to-treat in comparative effectiveness research.
    Hernán MA; Hernández-Díaz S
    Clin Trials; 2012 Feb; 9(1):48-55. PubMed ID: 21948059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.